自屏蔽陀螺放射外科(GRS)代表了立体定向放射外科领域的技术创新。GRS不需要放射拱顶,并且针对放射外科治疗进行了优化。有关其使用情况的报告有限。我们描述了GRS在我们机构的首次临床经验,以评估GRS在颅骨肿瘤治疗中的应用。此外,我们对机器人放射外科(RRS)与前庭神经鞘瘤(VS)GRS患者进行了剂量学比较。
包括2021年7月至11月间接受GRS治疗的患者。病人,肿瘤,并对剂量学特点进行回顾性总结和分析。
纳入41例颅内肿瘤患者48例。肿瘤实体主要包括VS,脑转移瘤,和脑膜瘤.良性肿瘤的中位处方剂量和等剂量线为13.5Gy和50.0%,恶性肿瘤为20Gy和60.0%,分别。平均计划目标体积为1.5立方厘米。所有患者都接受了单次治疗,没有遇到任何技术设置困难。治疗计划与RRS比较显示出可比的计划特征,剂量梯度,和处于危险剂量的器官。在新的符合性指数和每次治疗的监测单位数方面发现了显着差异(均P<0.01)。
本系列病例提供了更多关于在颅骨肿瘤治疗中使用自屏蔽GRS的证据。VS病例的剂量学比较显示出与RRS几乎相等的剂量学特征。GRS的进一步临床和物理分析正在进行中。
Self-shielding gyroscopic radiosurgery (GRS) represents a technical innovation in the field of stereotactic radiosurgery. GRS does not require a radiation vault and is optimized for radiosurgical treatments.
Reports on its usage are limited. We describe the first clinical experience of GRS at our institution to assess the application of GRS in the treatment of cranial tumors. Moreover, we perform a dosimetric comparison to robotic radiosurgery (RRS) with vestibular schwannoma (VS) GRS patients.
Patients who were treated with GRS between July and November 2021 were included. Patient, tumor, and dosimetric characteristics were retrospectively summarized and analyzed.
Forty-one patients with 48 intracranial tumors were included. Tumor entities mostly comprised VS, brain metastases, and meningiomas. The median prescription dose and isodose line were 13.5 Gy and 50.0% for benign neoplasia versus 20 Gy and 60.0% for malignant tumors, respectively. The mean planning target volume was 1.5 cubic centimeters. All patients received a single-fraction treatment without encountering any technical setup difficulties. Treatment plan comparisons with RRS revealed comparable plan characteristics, dose gradients, and organs at risk doses. Significant differences were detected concerning the new conformity index and number of monitor units per treatment (both P < 0.01).
This
case series provides more evidence on the usage of self-shielding GRS in the management of cranial tumors. Dosimetric comparisons for VS cases revealed mostly equivalent dosimetric characteristics to RRS. Further clinical and physical analyses for GRS are underway.